Genset Counts on Bioinformatics Strength For Near-Term Results from SNP Data | GenomeWeb

PARIS--Genset’s CEO Pascal Brandys said this month that now is a “crucial time” for his company to aggressively exploit genomic data to create “multiple medically valuable assets.” Toward that end, the company recently raised over ¥49 million through issuance of convertible bonds exchangeable into Genset common shares. It has also, over the past year, established a formidable in-house bioinformatics presence.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.